MX367012B - Agentes de union al receptor de la region constante fc de inmunoglobulina. - Google Patents

Agentes de union al receptor de la region constante fc de inmunoglobulina.

Info

Publication number
MX367012B
MX367012B MX2013008414A MX2013008414A MX367012B MX 367012 B MX367012 B MX 367012B MX 2013008414 A MX2013008414 A MX 2013008414A MX 2013008414 A MX2013008414 A MX 2013008414A MX 367012 B MX367012 B MX 367012B
Authority
MX
Mexico
Prior art keywords
constant region
receptor binding
binding agents
replacement compounds
immunoglobulin constant
Prior art date
Application number
MX2013008414A
Other languages
English (en)
Inventor
Olsen Henrik
E Strome Scott
H Schulze Dan
S Block David
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX367012B publication Critical patent/MX367012B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico recombinante, caracterizada porque comprende una secuencia que codifica una proteína monomérica de unidad de stradomer de agrupación que comprende un dominio Fc de Ig1 y un dominio de multimerización de articulación de IgG2 en donde la unidad de stradomer de agrupación multimeriza a través del dominio de multimerización de articulación de IgG2 para formar un stradomer de agrupación que es capaz de unirse a dos o más receptores Fc?, la unidad de stradomer de agrupación y el uso de la unidad de estradomer.
MX2013008414A 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina. MX367012B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94164407P 2007-06-01 2007-06-01
US1512707P 2007-12-19 2007-12-19
US1554707P 2007-12-20 2007-12-20
PCT/US2008/065428 WO2008151088A2 (en) 2007-06-01 2008-05-30 Immunoglobulin constant region fc receptor binding agents

Publications (1)

Publication Number Publication Date
MX367012B true MX367012B (es) 2019-08-02

Family

ID=40094382

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013008414A MX367012B (es) 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina.
MX2009013004A MX2009013004A (es) 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina.
MX2019009211A MX394440B (es) 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2009013004A MX2009013004A (es) 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina.
MX2019009211A MX394440B (es) 2007-06-01 2008-05-30 Agentes de union al receptor de la region constante fc de inmunoglobulina.

Country Status (17)

Country Link
US (11) US8680237B2 (es)
EP (3) EP3409687A1 (es)
JP (3) JP5600588B2 (es)
KR (2) KR101580937B1 (es)
CN (3) CN103897063B (es)
AU (1) AU2008259946B2 (es)
BR (1) BRPI0812248B8 (es)
CA (1) CA2688490C (es)
DK (1) DK2185589T3 (es)
ES (1) ES2565834T3 (es)
HU (1) HUE026953T2 (es)
IL (5) IL202409A (es)
MX (3) MX367012B (es)
PL (1) PL2185589T3 (es)
RU (3) RU2549676C2 (es)
SI (1) SI2185589T1 (es)
WO (1) WO2008151088A2 (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1167139A (ja) * 1997-08-25 1999-03-09 Hitachi Ltd 走査電子顕微鏡
MX367012B (es) 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US9395365B2 (en) * 2009-04-02 2016-07-19 Abbott Point Of Care, Inc. Detection of infectious disease in a human or animal by measuring specific phagocytosis in a thin film sample of their anticoagulated blood
US20130189247A1 (en) * 2010-02-12 2013-07-25 Research Corporation Technologies, Inc. Multimeric Proteins Comprising Immunoglobulin Constant Domains
AU2015200330B2 (en) * 2010-07-28 2016-10-27 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1203528A1 (zh) * 2012-01-27 2015-10-30 Gliknik Inc. 包含igg2鉸鏈結構域的融合蛋白
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2885320A4 (en) * 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
AU2012392760C1 (en) * 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
WO2014103534A1 (ja) * 2012-12-28 2014-07-03 国立大学法人大阪大学 コラーゲン結合性分子を付加した改変ラミニンおよびその利用
US9220824B2 (en) 2013-01-08 2015-12-29 AdjuCor GmbH Implanting cardiac devices
DE102013200151A1 (de) 2013-01-08 2014-07-10 AdjuCor GmbH Herzunterstützungsvorrichtung mit Markierungen
DE102013200148B4 (de) 2013-01-08 2026-01-08 AdjuCor GmbH Steckersystem für eine Herzunterstützungsvorrichtung
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US9486311B2 (en) 2013-02-14 2016-11-08 Shifamed Holdings, Llc Hydrophilic AIOL with bonding
US10195018B2 (en) 2013-03-21 2019-02-05 Shifamed Holdings, Llc Accommodating intraocular lens
EP4257359A3 (en) 2013-03-21 2023-12-06 Shifamed Holdings, LLC Accommodating intraocular lens
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PL3087095T3 (pl) * 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
CA2983796A1 (en) * 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA2959354C (en) 2014-08-26 2018-08-21 Shifamed Holdings, Llc Accommodating intraocular lens
CN107427573B (zh) 2014-12-24 2022-12-27 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
DE102015212699A1 (de) * 2015-07-07 2017-01-12 AdjuCor GmbH Implantierbare Vorrichtung zur ortsgenauen Zuführung und Applikation von Substanzen in das Perikard oder auf die Herzoberfläche
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017059276A2 (en) 2015-10-02 2017-04-06 Momenta Pharmaceuticals, Inc. Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11141263B2 (en) 2015-11-18 2021-10-12 Shifamed Holdings, Llc Multi-piece accommodating intraocular lens
WO2017087358A1 (en) 2015-11-18 2017-05-26 Shifamed Holdings, Llc Multi-piece accommodating intraocular lens
WO2017087825A1 (en) 2015-11-19 2017-05-26 Asclepix Therapeutics, Llc. Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
ES2972740T3 (es) * 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
JP7657014B2 (ja) 2016-03-07 2025-04-04 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
WO2017172853A1 (en) * 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
PL3484514T3 (pl) * 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
DE112017003223T5 (de) 2016-06-28 2019-03-21 Hitachi Automotive Systems, Ltd. Scheibenbremse
MX2019000887A (es) 2016-07-22 2019-09-04 Gliknik Inc Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
CA3038809A1 (en) 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc. Compounds and methods for activating tie2 signaling
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
KR102729723B1 (ko) * 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
JP7519774B2 (ja) 2016-12-09 2024-07-22 グリックニック インコーポレイテッド 多価ｆｃ化合物を用いる炎症性疾患の治療方法
US10350056B2 (en) 2016-12-23 2019-07-16 Shifamed Holdings, Llc Multi-piece accommodating intraocular lenses and methods for making and using same
EP4512370A3 (en) 2016-12-23 2025-04-30 Shifamed Holdings, LLC Multi-piece accommodating intraocular lenses and methods for making and using same
BR112019013955A2 (pt) * 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3052523A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
KR20180093234A (ko) 2017-02-11 2018-08-21 이도훈 공기 주입식 컵홀더
CN108530517A (zh) * 2017-03-01 2018-09-14 拜西欧斯（北京）生物技术有限公司 刺激免疫细胞活化的多肽、融合蛋白及其制备方法
PL3431105T3 (pl) 2017-03-29 2020-11-02 Shionogi & Co., Ltd. Kompozycja lecznicza do leczenia raka
CN114989305A (zh) * 2017-03-31 2022-09-02 北京智仁美博生物科技有限公司 新型双特异性抗体及其用途
EP3634308A4 (en) 2017-05-30 2021-02-24 Shifamed Holdings, LLC SURFACE TREATMENTS FOR ACCEPTING INTRAOCULAR LENSES AND RELATED PROCEDURES AND DEVICES
JP7082822B2 (ja) 2017-06-07 2022-06-09 シファメド・ホールディングス・エルエルシー 調整可能な屈折力の眼内レンズ
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
ES2911243T3 (es) * 2017-08-10 2022-05-18 Grifols Diagnostic Solutions Inc Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
US12059476B2 (en) 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US20210095006A1 (en) 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
AU2019215440B2 (en) 2018-02-05 2025-12-04 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
GB201804243D0 (en) * 2018-03-16 2018-05-02 Liverpool School Tropical Medicine Hinge sequences
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
KR20210042326A (ko) * 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
WO2020014505A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
WO2020102605A1 (en) * 2018-11-15 2020-05-22 The Regents Of The University Of California Vesicle-coated fibers and methods of making and using
WO2020148336A1 (en) * 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
KR20200099807A (ko) * 2019-02-15 2020-08-25 아주대학교산학협력단 항체의 불변부위로만 구성된 항체 단편 및 이의 용도
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用
JP7616671B2 (ja) 2019-06-24 2025-01-17 ウニヴェルズィテート シュトゥットガルト 改善された安定性を有するｔｎｆｒ２アゴニスト
WO2021007535A1 (en) 2019-07-11 2021-01-14 Shifamed Holdings, Llc Accommodating intraocular lenses and associated methods
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
CN110669134A (zh) * 2019-10-15 2020-01-10 广东菲鹏生物有限公司 IgM-FC片段、IgM-FC抗体及制备方法和应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN114786721B (zh) 2019-12-06 2025-10-17 康诺贝林伦瑙有限公司 Fc多聚体的稳定组合物
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
AU2021329742B2 (en) * 2020-08-21 2025-12-11 Fatiabgen Inc. Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (CΓ1) and epsilon constant region (CE2-4) are fused, and use thereof
CR20230204A (es) 2020-10-14 2023-10-11 Viridian Therapeutics Inc Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
EP4295154A1 (en) * 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
CN113358546A (zh) * 2021-04-21 2021-09-07 贵州安康医学检验中心有限公司 一种自身免疫性周围神经病相关抗体的联合检测方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
CN114478806B (zh) * 2022-04-14 2022-07-01 呈诺再生医学科技(北京)有限公司 一种提升免疫细胞杀伤活性的嵌合受体及其应用
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
EP4551600A1 (en) 2022-07-04 2025-05-14 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
CN121358771A (zh) 2023-04-03 2026-01-16 非营利性组织佛兰芒综合大学生物技术研究所 血-脑屏障穿越抗体
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
TW202535948A (zh) 2023-12-17 2025-09-16 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025185753A1 (zh) * 2024-03-08 2025-09-12 祝道成 融合蛋白吸入剂治疗呼吸道过敏性疾病

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
IL102915A (en) 1992-01-19 2005-12-18 Yeda Res & Dev Soluble ldl receptor and its preparation
JPH08503125A (ja) 1992-08-07 1996-04-09 プロジェニクス・ファーマスーティカルス・インコーポレーテッド 非ペプチジル成分と複合化されたＣＤ４−ガンマ２およびＣＤ４−ＩｇＧ２免疫複合体、並びにその使用
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
EP1082137A4 (en) 1998-05-06 2004-05-19 Univ Temple REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US20020142374A1 (en) * 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2001049318A1 (en) 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
JP2004524019A (ja) 2001-01-12 2004-08-12 ベクトン・ディキンソン・アンド・カンパニー 内因性蛍光自己多量体化ｍｈｃ融合タンパク質およびその複合体
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
AU2002315052A1 (en) 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003051933A1 (en) 2001-12-18 2003-06-26 Dow Corning Toray Silicone Co., Ltd. Photocurable organic polymer composition
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US7427471B2 (en) 2002-06-14 2008-09-23 Centocor, Inc. Modified “S” antibodies
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP2052713A3 (en) 2003-01-13 2009-05-20 Macrogenics, Inc. Soluble FcgammaR fusion proteins and methods of use thereof
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CA2527878A1 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2006071206A2 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
WO2006008739A2 (en) * 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
EP1824979A2 (en) * 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
CA2605401A1 (en) 2005-04-19 2006-10-26 University Of Maryland Compositions and methods for modulating interleukin-10
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
RU2428430C2 (ru) * 2005-08-16 2011-09-10 Ханми Холдингс Ко., Лтд. СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2007094005A2 (en) 2006-02-17 2007-08-23 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
US20090304715A1 (en) 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
PL2158319T4 (pl) 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
MX367012B (es) 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
HUE029454T2 (en) 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
EP2588123A2 (en) 2010-06-30 2013-05-08 Compugen Ltd. C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
HK1203528A1 (zh) 2012-01-27 2015-10-30 Gliknik Inc. 包含igg2鉸鏈結構域的融合蛋白
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
WO2016073917A1 (en) 2014-11-06 2016-05-12 Gliknik Inc. Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose

Also Published As

Publication number Publication date
US20170218049A1 (en) 2017-08-03
EP2641913A3 (en) 2013-11-27
EP3409687A1 (en) 2018-12-05
KR20100028599A (ko) 2010-03-12
US20140335075A1 (en) 2014-11-13
WO2008151088A8 (en) 2009-07-02
KR20140139619A (ko) 2014-12-05
IL255334A0 (en) 2017-12-31
IL279683A (en) 2021-03-01
US9512210B2 (en) 2016-12-06
RU2729829C2 (ru) 2020-08-12
BRPI0812248B1 (pt) 2021-03-23
JP5600588B2 (ja) 2014-10-01
JP6215365B2 (ja) 2017-10-18
WO2008151088A2 (en) 2008-12-11
MX2009013004A (es) 2010-01-20
US8680237B2 (en) 2014-03-25
RU2015107693A (ru) 2015-10-20
CN101835802B (zh) 2014-04-09
ES2565834T3 (es) 2016-04-07
US20120309941A1 (en) 2012-12-06
US9926362B2 (en) 2018-03-27
PL2185589T3 (pl) 2016-09-30
CN107011445B (zh) 2021-06-29
CN103897063A (zh) 2014-07-02
RU2009148295A (ru) 2011-07-20
EP2641913B1 (en) 2018-04-18
CA2688490C (en) 2022-06-21
KR101580937B1 (ko) 2015-12-31
IL290995A (en) 2022-05-01
CN103897063B (zh) 2017-04-12
US20190218275A1 (en) 2019-07-18
BRPI0812248A2 (pt) 2017-05-02
KR101580938B1 (ko) 2015-12-30
CN101835802A (zh) 2010-09-15
JP2014138595A (ja) 2014-07-31
MX394440B (es) 2025-03-24
US20160280768A1 (en) 2016-09-29
IL279683B (en) 2022-04-01
BRPI0812248B8 (pt) 2021-05-25
US20210277091A1 (en) 2021-09-09
US10851154B2 (en) 2020-12-01
MX2019009211A (es) 2019-09-13
RU2015107693A3 (es) 2018-11-12
WO2008151088A3 (en) 2009-04-02
IL202409A0 (en) 2011-08-01
EP2185589A2 (en) 2010-05-19
EP2185589B1 (en) 2016-01-06
US9512208B2 (en) 2016-12-06
JP2010529043A (ja) 2010-08-26
EP2641913A2 (en) 2013-09-25
DK2185589T3 (en) 2016-03-21
JP2016127834A (ja) 2016-07-14
US20100239633A1 (en) 2010-09-23
US10941191B2 (en) 2021-03-09
WO2008151088A9 (en) 2010-03-04
JP5870134B2 (ja) 2016-02-24
HUE026953T2 (en) 2016-08-29
IL255334B (en) 2021-01-31
AU2008259946B2 (en) 2013-08-29
AU2008259946A1 (en) 2008-12-11
RU2020125144A (ru) 2022-01-31
CA2688490A1 (en) 2008-12-11
IL202409A (en) 2015-11-30
US20150056185A1 (en) 2015-02-26
SI2185589T1 (sl) 2016-04-29
IL242536A (en) 2017-11-30
EP2185589A4 (en) 2010-06-23
CN107011445A (zh) 2017-08-04
US20160355570A1 (en) 2016-12-08
RU2549676C2 (ru) 2015-04-27
US20140105913A1 (en) 2014-04-17
US20180186862A1 (en) 2018-07-05
US10208105B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
MX367012B (es) Agentes de union al receptor de la region constante fc de inmunoglobulina.
TW200642694A (en) Anti-M-CSF antibody compositions
NZ705848A (en) Anti-cd38 antibodies
MX2021004059A (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
SG196821A1 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
MY154009A (en) Anti-alpha v beta 6 antibodies
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
IL245462A0 (en) Antagonists of human origin against cmet
MX336807B (es) Composiciones y metodos para producir una composicion.
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
LT2990422T (lt) Humanizuoti anti-beta7 antagonistai ir jų panaudojimas
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
WO2012012531A3 (en) Compositions and methods featuring il-6 and il-21 antagonists